CLEARSIDE BIOMEDICAL INC (CLSD) Stock Price & Overview
NASDAQ:CLSD • US1850632035
Current stock price
The current stock price of CLSD is 0.41 USD. Today CLSD is down by -26.96%. In the past month the price decreased by -89.12%. In the past year, price decreased by -97.4%.
CLSD Key Statistics
- Market Cap
- 2.144M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -5.19
- Dividend Yield
- N/A
CLSD Stock Performance
CLSD Stock Chart
CLSD Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to CLSD. When comparing the yearly performance of all stocks, CLSD is a bad performer in the overall market: 99.82% of all stocks are doing better.
CLSD Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLSD. CLSD may be in some trouble as it scores bad on both profitability and health.
CLSD Earnings
On November 14, 2025 CLSD reported an EPS of -1.14 and a revenue of 201.00K. The company missed EPS expectations (-112.89% surprise) and missed revenue expectations (-14.32% surprise).
CLSD Forecast & Estimates
11 analysts have analysed CLSD and the average price target is 61.2 USD. This implies a price increase of 14826.83% is expected in the next year compared to the current price of 0.41.
For the next year, analysts expect an EPS growth of 56.93% and a revenue growth 102.46% for CLSD
CLSD Groups
Sector & Classification
CLSD Financial Highlights
Over the last trailing twelve months CLSD reported a non-GAAP Earnings per Share(EPS) of -5.19. The EPS increased by 19.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.75% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CLSD Ownership
CLSD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 26.76 | 882.589B | ||
| JNJ | JOHNSON & JOHNSON | 20.87 | 585.389B | ||
| MRK | MERCK & CO. INC. | 23.36 | 298.838B | ||
| PFE | PFIZER INC | 9.48 | 161.094B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.41 | 121.374B | ||
| ZTS | ZOETIS INC | 16.66 | 49.786B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.4 | 28.018B | ||
| VTRS | VIATRIS INC | 5.36 | 15.475B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.94 | 11.475B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.619B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 6.372B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 5.599B | ||
| CORT | CORCEPT THERAPEUTICS INC | 51.43 | 4.52B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLSD
Company Profile
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
Company Info
IPO: 2016-06-02
CLEARSIDE BIOMEDICAL INC
900 North Point Parkway, Suite 200
Alpharetta GEORGIA 30005 US
CEO: George Lasezkay
Employees: 32
Phone: 16782703631
CLEARSIDE BIOMEDICAL INC / CLSD FAQ
What does CLSD do?
Clearside Biomedical, Inc. is a biopharmaceutical company that delivers therapies to the back of the eye through the suprachoroidal space. The company is headquartered in Alpharetta, Georgia and currently employs 32 full-time employees. The company went IPO on 2016-06-02. The firm's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The firm is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The firm's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD). The company developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.
What is the stock price of CLEARSIDE BIOMEDICAL INC today?
The current stock price of CLSD is 0.41 USD. The price decreased by -26.96% in the last trading session.
What is the dividend status of CLEARSIDE BIOMEDICAL INC?
CLSD does not pay a dividend.
What is the ChartMill rating of CLEARSIDE BIOMEDICAL INC stock?
CLSD has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does CLEARSIDE BIOMEDICAL INC belong to?
CLEARSIDE BIOMEDICAL INC (CLSD) operates in the Health Care sector and the Pharmaceuticals industry.
What is the expected growth for CLSD stock?
The Revenue of CLEARSIDE BIOMEDICAL INC (CLSD) is expected to grow by 102.46% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of CLEARSIDE BIOMEDICAL INC (CLSD)?
You can find the ownership structure of CLEARSIDE BIOMEDICAL INC (CLSD) on the Ownership tab.